The efficacy of intravenous thrombolysis in acute ischemic stroke patients with white matter hyperintensity

Brain Behav. 2018 Dec;8(12):e01149. doi: 10.1002/brb3.1149. Epub 2018 Oct 31.

Abstract

Objectives: We aimed to investigate effects of deep white matter hyperintensity (DWMH) and periventricular hyperintensity (PVH) on the efficacy of intravenous thrombolysis (IVT) in patients with acute ischemic stroke (AIS).

Methods: A total of 113 AIS patients with WMH were categorized into the PVH group and the DWMH group according to the lesion location, with the division of two subgroups based on whether or not they received IVT treatment: the thrombolysis group and the control group. Kaplan-Meier analysis was used for proportional hazards of recurrent stroke. Further, multivariate Cox regression analysis was employed.

Results: Of total patients, there were 62 PVH patients and 51 DWMH patients: 27 of PVH patients and 22 of DWMH patients received IVT, and the remaining patients only received routine treatment. DWMH patients had a higher risk of END (36.4% vs. 11.1%; p = 0.034) and HT (22.7% vs. 3.7%; p = 0.038) than PVH patients in the thrombolysis group. Moreover, DWMH patients undergoing IVT also had a higher risk of END (36.4% vs. 10.3%; x2 = 5.050; p = 0.025) and HT (22.7% vs. 3.4%; x2 = 4.664; p = 0.031) than DWMH patients without IVT. Again, PVH patients had a higher rate of recurrent stroke (20.0% vs. 3.4%; p = 0.034) than DWMH patients in the control group after 90-day follow-up. Kaplan-Meier analysis showed a significant difference in cumulative probability of no major endpoint events (p = 0.039). Further, multivariate Cox regression revealed that PVH is an independent risk factor for stroke recurrence in AIS patients after adjusting confounding factors.

Conclusions: The location of WMH is closely associated with the efficacy of IVT in AIS patients.

Keywords: acute ischemic stroke; deep white matter hyperintensity; efficacy; intravenous thrombolysis; periventricular hyperintensity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / pathology
  • Epidemiologic Methods
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Humans
  • Injections, Intravenous
  • Leukoencephalopathies / pathology
  • Magnetic Resonance Imaging
  • Male
  • Recombinant Proteins / administration & dosage
  • Stroke / drug therapy*
  • Stroke / pathology
  • Thrombolytic Therapy / methods*
  • Tissue Plasminogen Activator / administration & dosage*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Recombinant Proteins
  • Tissue Plasminogen Activator